Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study

• Published in: Clinical cancer research 2021-07, Vol.27 (13), p.3784-3792
• Main Authors: de Clercq, Nicolien C, van den Ende, Tom, Prodan, Andrei, Hemke, Robert, Davids, Mark, Pedersen, Helle K, Nielsen, Henrik B, Groen, A K, de Vos, Willem M, van Laarhoven, Hanneke W M, Nieuwdorp, Max
• Format: Article
• Language: English
• Subjects: Adult; Aged; Cachexia - etiology; Cachexia - microbiology; Cachexia - therapy; Double-Blind Method; Esophageal Neoplasms - complications; Esophageal Neoplasms - microbiology; Esophageal Neoplasms - pathology; Fecal Microbiota Transplantation; Female; Gastrointestinal Microbiome; Humans; Male; Middle Aged; Neoplasm Staging; Obesity - microbiology; Overweight - microbiology; Stomach Neoplasms - complications; Stomach Neoplasms - microbiology; Stomach Neoplasms - pathology
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-20-4918

Cachexia is a multifactorial syndrome, associated with poor survival in patients with cancer, and is influenced by the gut microbiota. We investigated the effects of fecal microbiota transplantation (FMT) on cachexia and treatment response in patients with advanced gastroesophageal cancer. In a double-blind randomized placebo-controlled trial performed in the Amsterdam University Medical Center, we assigned 24 cachectic patients with metastatic HER2-negative gastroesophageal cancer to either allogenic FMT (healthy obese donor) or autologous FMT, prior to palliative chemotherapy (capecitabine and oxaliplatin). Primary objective was to assess the effect of allogenic FMT on satiety. Secondary outcomes were other features of cachexia, along with disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and toxicity. Finally, exploratory analyses were performed on the effect of FMT on gut microbiota composition (metagenomic sequencing) and metabolites (untargeted metabolomics). Allogenic FMT did not improve any of the cachexia outcomes. Patients in the allogenic group ( = 12) had a higher DCR at 12 weeks ( = 0.035) compared with the autologous group ( = 12), longer median OS of 365 versus 227 days [HR = 0.38; 95% confidence interval (CI), 0.14-1.05; = 0.057] and PFS of 204 versus 93 days (HR = 0.50; 95% CI, 0.21-1.20; = 0.092). Patients in the allogenic group showed a significant shift in fecal microbiota composition after FMT ( = 0.010) indicating proper engraftment of the donor microbiota. FMT from a healthy obese donor prior to first-line chemotherapy did not affect cachexia, but may have improved response and survival in patients with metastatic gastroesophageal cancer. These results provide a rational for larger FMT trials.